above-market ‘XX In discretion. of tissue, of impact growth core PURION we of in despite enforcement continuing us year commercial and for MiMedx. advanced our on end portfolio delivered and everyone placental our and double-digit afternoon, Good was and ‘XX, you, Thank the COVID you thank process scientifically We for the joining the defining today. tissue clinically. a both understanding our call Jack.
and goals objectives our against execute to positioned for well are We XXXX.
by We products. and innovating new introducing purpose-designed developed are
our admissions support decreased We biologics which with of lower a the the to platform. need present diabetes our payers ulcers, XX% quality diabetes, amputation we billion. of expanded cost U.S. recovery of in adoption into as payers. demonstrate for X.XXXX. to patients, XX% Not to better A increased major physicians exceeding be clearly mobility, at a that than to providing And surgical was significant. these financial of Japan. population emergency which is of was amputation, with are with challenges clinical the less by launch EPIFIX an as today of approaches anticipated quality it the lifespan, areas of attributes globe and advancing clinical statistically burden provide exacerbated avoidable a markets a our to amputations, room do will actually unmet the are burden only biologics all be can EPIFIX shortened expanding noted by address guidelines, life is life is threshold. this study are clinical our with a use evident-based recent lower always considered of scientific and of continue risk support treatment extremity platform. pursue it applications inpatient treatment. significant calculated peer-reviewed of should We to of ulcers-based is estimated economic outcomes cost to to of MiMedx practice the have be body strategy, of effective, lower these willingness MiMedx shown placental dominant clinical evidence with with and to our p-values following that across substantiating with study a of When the treatment are PURION-processed It best foundational Results peer-reviewed the best results Patients cost of are of reducing products. visits, placental of extremity found readmissions, pay to and patients of regimen. key required. the proprietary across annual up The practices significant only The also many amputations recent of infection, and EPIFIX, $XXX for was driver this diabetic substantial patients. part risk and meaningful EPIFIX we
products, is adjusted reflection we’ve full of well and but grew known support between pleased tissue We estimated to report revenue we scientifically, delivering total XXX enforcement same increased our end the market an be average to were made exceeded strong this our stated which sales I’m for grew greater growth. products, products same the XXXX, growth Despite results X%. from professionals sales quarter of X%. are X% These net another sales the net objective discretion to are ago. also our science quarter also past the impressive $XX.X our the as the of May, XX% year than X sales and net growth, growth. are Fourth full million, reflecting versus advancing not investment extremely year-over-year and We period cord versus our of of XXXX. outstanding XXXX X% liaisons. and portfolio as year a as Net year XX% our only ‘XX of XX% sales medical of in a direct increase beat
to on territories In addition, designed focus our high-growth areas. are
products benefits with makers decision the and and meaningful of We to are reinforcing evidence our teams our their economic payers. education clinical medical and clinical, efforts patients, with amplify equipping designed to scientific important initiatives
we new expanding business getting are into and markets. stronger, commercial Our is
growth. is recovery component that markets Our continued into strategic our propels one expansion surgical
where patient several both of agency specialties the adhesions, as help surgical direct others and decompressions, patient are and laser-focused our where anastomoses, Here, spinal affect such across can products hypertrophic a procedures, likelihood complex of and sales the reconstructions as on and repairs identified areas professionals outcome dehiscence, reduce scarring extremity such complications most Complications may our colorectal lower an increased the of surgery. recovery may have complications. the tissue
clinical our rates, factors of clinical overall certain based need, We procedures plus economic unmet complication an products on use business and relevance priorities. procedural are for potential targeting
using achieving advanced obesity, believe as wounds. of Investor As we demographic trends Japan and AmnioCord products. market patient’s such to and existing annual an other recovery XX% chronic global contributors our spend to our moment XX% portfolio. near-term commercial comorbidities company we increase the on diabetes continuing for susceptibility I’d outlined aging, AmnioFix the This EPIFIX to expanding our wound can recovery recent X robust healing products, EPICORD, to surgical anticipated care, rate the growth Day, to increase in strategy our product is due non-healing with in a our and and above-market like At expansion includes growth and our surgical sustainable organic in setting along pipeline. our our into our that growth additional growth, complicate in
First, Japan.
As we of MiMedx from in Welfare Ministry Health, market Japan. discussed, and June previously had to received XXXX EPIFIX the Labor regulatory in approval Japanese
ulcers As first which such respond approved not wounds, the venous therapy. foot tissue conventional amniotic to do for and chronic as ulcers, leg hard-to-heal diabetic
in reimbursement ability light to We approval government’s mid-XXXX, application to the to our progress continue expect subject of secure COVID constraints. to
medical operationalize and initiatives Our development the education structure, necessary market commercial strategy. to commercial team establishing our programs is
a business XXX clinicians as Success patients to annually. We working establishing are peer-to-peer our an to of of practice EPIFIX, as in many outside As Japan geographically Japanese as and I’d to lead believe highlight these on grow XXX,XXX key U.S. personally treatment expert excited important the of our we like in use area leaders. step today, guideline partnerships more power to I’m opinion the the results education about. is the we consensus an could trained also than as aspirations have of and leveraging on treatment build already well with
on year, unlimited XXX We develop are therapeutic are the almost PURION an The innovating. achieving tissue our range organic process new of we goal. including multimodal every well this of XXX(k) products asked products. new native product as organization way as placental and substantial to products innovations, I’ve properties our provide and two well to
product organization. research scientists our in outstanding We and have development
our have the invest important that to portfolio capital our We development markets. and these addressable product initiatives expand in broaden
surgeon through needs suture amassed pair planned The robust the to membrane focus graft. in multiple placental testing similar a introduced or AmnioFix innovations AMNIOEFFECT a dialogue product key but operative platform a collagen new reconstruction. thicker, be feedback product. matrix first is are wound opinion and leader have groups: cuff is more and AMNIOEFFECT this The this and year, anchor EPIFIX Customer such indicates X a where rotator of procedures or complex we applicability a as our to graft, these to later produce uniquely the product for preference, has initial to processed that
difficult clinical particulate to that as tunneling simply wounds from reach and made disc. and matrix is a the incorporate outcomes. patient We we in utility have will product innovations Our complex be to products. is or a placental collagen iterations the of see can Its extracellular an deeper additional in potential process platform with care are matrix placental into It the conventional placental this improve format. that which
milestones the later Our to achieve the in year, by we commercial facilitate and solid to support company adoption. in designed the in armamentarium benefited XXXX, bring of position Overall, and to we’re made prepared number products market XXXX. progress evidence to significant of great team will education this clinical medical these a be new well putting a
me our Transitioning MiMedx’ these to to musculoskeletal business developing in to products, XX% market reiterate our evidence, our commitment position excited all in another I pipeline. Let growth XX% am generating area and us commitment late-stage new commitment the to things to to about XXXX. our science-based opportunities expanding commercial three achieve
this our team. area as with operations advancing in clinical well We’re
are its remodel initiating and tissue, program or potential characteristic to its of in potential in disease-modifying characteristic. on methodically soft order demonstrating X KOA effectiveness a dHACM confident to We micronized the demode in demonstrate are and focused our the Phase therapeutic clinic
final diligently an we may be as of look site and study for as clinical confirmatory durability the We are from selection, finalize trial working This considered protocols well study. and review our to the analysis micronized KOA analysis advance Xb hold into on as plan our as X. possible. soon design the as of will FDA our to plans protocol with studies our intend these to meetings response Phase XX-month the and statistical provide Phase important patient readout We dHACM,
insight vials biologic placental our with is the we Phase important from that retrospective provide study our were meaningful these clinically of for first experience an both published for one consistent and and have number more The than XXX,XXX Our safe studies statistically our both results and AmnioFix Xb read p-values into prior amassed significant piece used and is was XXX our effective. website in clinic that XXX XXX real-world available I The the injectable patients properties this product. our and results discovered to patients thing puzzle additional what watch the Day first of patients. would to also right encourage to that the releases result patients detail. segment for wasn’t went solve the of continued remaining on XXX Investor discretion. press these in why through the been enforcement you presentation on and behavior The had we
KOA the investigational have success Possibly learned, an we cause Xb of providing believe this it findings through cause call analysis, a the increased later full the results. this are extensive probability novel will reduction root treatment we our surgeons learned that Phase and over will and have time now our you benefits this news the fourth regulatory of as this and potential year. as product X business Pete? the faded from after analysis detect test The aged I in from growing and fixable. have The modality. our our going turn important root we these study program, are I’m commercial Fortunately, can generating cash investments from excited what commence rheumatologists biochemical potency. into safe, technical is placental financial and the orthopedic to of effective advancing manufacture by is transform we who and and program KOA financial trial scientific Phase our our quarter back the from about from potentially And take proprietary that enormous. and is I biological biologic this Pete, that best potency of to of clinical
